The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples

Leukemia & Lymphoma
Claudia M WeverNathalie A Johnson

Abstract

Relapse occurs in 10-40% of Burkitt lymphoma (BL) patients that have completed intensive chemotherapy regimens and is typically fatal. While treatment-naive BL has been characterized, the genomic landscape of BL at the time of relapse (rBL) has never been reported. Here, we present a genomic characterization of two rBL patients. The diagnostic samples had mutations common in BL, including MYC and CCND3. Additional mutations were detected at relapse, affecting important pathways such as NFκB (IKBKB) and MEK/ERK (NRAS) signaling, glutamine metabolism (SIRT4), and RNA processing (ZFP36L2). Genes implicated in drug resistance were also mutated at relapse (TP53, BAX, ALDH3A1, APAF1, FANCI). This concurrent genomic profiling of samples obtained at diagnosis and relapse has revealed mutations not previously reported in this disease. The patient-derived cell lines will be made available and, along with their detailed genetics, will be a valuable resource to examine the role of specific mutations in therapeutic resistance.

References

Jan 15, 1976·International Journal of Cancer. Journal International Du Cancer·L ZechG Klein
Dec 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R Dalla-FaveraC M Croce
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S KaulP O'Dwyer
Mar 15, 1994·Biochemical and Biophysical Research Communications·G YamadaP Gruss
Dec 1, 1993·Mammalian Genome : Official Journal of the International Mammalian Genome Society·M HaasB Rudy
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I MagrathI D Horak
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J O Armitage, D D Weisenburger
Aug 12, 1999·Biochemical and Biophysical Research Communications·C HahnH Stein
Dec 23, 1999·Chemical Immunology·R L Kitchens
Aug 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·D W FelsherJ M Bishop
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·R D Levine, J L Kinsey
Jun 17, 2003·Molecular and Cellular Biology·G RadziwillK Moelling
Jan 21, 2004·The Journal of Surgical Research·Kathryn S NortonBenjamin D L Li
Feb 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Bettina MalnicLinda B Buck
Jun 9, 2004·Gene Expression Patterns : GEP·Young-Ki BaeMasahiko Hibi
Jul 22, 2004·Blood·Kristie A BlumJohn C Byrd
Jan 21, 2006·Science·Mary Grace GollTimothy H Bestor
Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen W L YeeFrancis J Giles
Jun 3, 2008·American Journal of Human Genetics·Jonna TallilaMarjo Kestilä
Oct 29, 2008·Oncogene·B Hoffman, D A Liebermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ryan D MorinNathalie A Johnson
Nihon rinsho. Japanese journal of clinical medicine
Takashi Watanabe
British Journal of Haematology
David C Linch
© 2022 Meta ULC. All rights reserved